Characteristics | All (N = 70) | |
No. | % | |
Age (years) |
| |
Mean ± SD | 50.24 ± 9.58 | |
Median (Range) | 52.50 (27 - 62) | |
Grade |
|
|
Low | 18 | 27.7% |
High | 52 | 74.3% |
LN |
|
|
Negative | 22 | 31.4% |
Positive | 48 | 68.6% |
Stage |
|
|
Stage I | 8 | 11.4% |
Stage II | 12 | 17.1% |
Stage III | 32 | 45.7% |
Stage IV | 18 | 25.7% |
CA125 (u/ml) |
| |
Mean ± SD | 1071.31 ± 666.91 | |
Median (Range) | 1238.50 (69 - 2008) | |
Gal-1 (ng/ml) |
| |
Mean ± SD | 334.84 ± 187.67 | |
Median (Range) | 277 (32 - 763) | |
Gal-1 |
|
|
Weak | 22 | 31.4% |
Strong | 48 | 68.6% |
Gal-1 tumor cells |
|
|
Weak | 24 | 34.3% |
Strong | 46 | 65.7% |
Follow-up duration (months) |
| |
Mean ± SD | 15.45 ± 8.45 | |
Median (Range) | 14 (3 - 36) | |
Outcome |
|
|
Alive | 54 | 77.1% |
Died | 16 | 22.9% |